INSIGHTS ON CLINICAL TRIAL PARTNERING

• How A Strategic Bioanalysis CRO Partnership Empowers Sponsors

  Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

• The Promise Of IQVIA One Home For Sites: A Site CEO's Perspective

  By providing research sites with a unified, streamlined interface, we can reduce operational friction, enhance collaboration, and ultimately accelerate the development of new therapies.

• Routes To Sponsor Of Choice: Shared Pipelines, Streamlined Payments

  Paying clinical trial sites consistently on time provides stability and maintains positive relationships. Learn why being a sponsor of choice can mean the adoption of a singular clinical trial payments solution.

• Ensure The Safe And Efficient Development Of High Potent Drug Products

  As your product transitions from clinical phases to commercial launch, flexible, globally compliant facilities stand ready to adapt to your evolving needs.

• Building A Gold Standard Trial Experience In Japan

  4/4/2025

  Hear how Medable worked with a Japanese sponsor to elevate their trial experience, achieve >90% patient and site adherence, and beat their forecasted FPI date, creating new eCOA standards adopted across all the customer’s vendors.

• Strategic Considerations For Oncology Trials In A Competitive Landscape

  5/14/2025

  By combining strategic foresight with hands-on support, the right partner accelerates oncology trial delivery and broadens access to promising therapies.

• Developing Community-Based And Trial-Naïve Sites: The Real ROI

  9/9/2025

  Trial-naïve sites, when supported with infrastructure, training, and network integration, represent a critical yet underused opportunity to expand patient access and accelerate recruitment.

• Stipends Create More Tax Burden — Here's A Better Option

  7/22/2025

  Explore the tax reporting requirements, including the threshold for payments requiring a 1099 form rising from $600 to $2,000 in 2026.

• Canadian CTA Frequently Asked Questions

  2/20/2024

  This FAQ list offers clarity on pivotal aspects of your drug development journey, ensuring studies in Canada pave the way for U.S. FDA and EMA submissions.